Watch Bio-Reference Laboratories'
What analysts say:
- Buy, sell, or hold?: Half of analysts think investors should stand pat on Bio-Reference Laboratories while the remaining half rate the stock as a buy. Analysts don't like Bio-Reference Laboratories as much as competitor MEDTOX Scientific overall. Two out of two analysts rate MEDTOX Scientific a buy compared to two out of four for Bio-Reference Laboratories. Bio-Reference Laboratories' rating hasn't changed over the past three months.
- Revenue forecasts: On average, analysts predict $143.1 million in revenue this quarter. That would represent a rise of 17.6% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.21 per share. Estimates range from $0.20 to $0.21.
What our community says:
CAPS All-Stars are solidly backing the stock, with 99% granting it an outperform rating. The greater community backs the All-Stars, as 94.8% give it a rating of outperform. Fools feel positively about Bio-Reference Laboratories, though the message boards have been quiet lately, with only one post in the past 30 days. Even with a robust four out of five stars, Bio-Reference Laboratories' CAPS rating falls a little short of the community's upbeat outlook.
Bio-Reference Laboratories' profit has risen year over year by an average of 45.6% over the past five quarters.
For all our Bio-Reference Laboratories-specific analysis, including earnings and beyond, add Bio-Reference Laboratories to My Watchlist.
The Motley Fool owns shares of Bio-Reference Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.Earnings estimates provided by Zacks.